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Background:  Globally,  BCG  vaccination  varies  in  efﬁcacy  and  has  some  non-speciﬁc  protective  effects.
Previous  studies  comparing  BCG  strains  have been  small-scale,  with  few or  no immunological  outcomes
and  have  compared  TB-speciﬁc  responses  only.  We  aimed  to evaluate  both  speciﬁc  and  non-speciﬁc
immune  responses  to  different  strains  of BCG  within  a  large  infant  cohort  and  to  evaluate  further  the
relationship  between  BCG  strain,  scarring  and  cytokine  responses.
Methods:  Infants  from  the Entebbe  Mother  and  Baby  Study  (ISRCTN32849447)  who  received  BCG-Russia,
BCG-Bulgaria  or BCG-Denmark  at birth, were  analysed  by  BCG strain  group.  At one  year,  interferon-
gamma  (IFN-),  interleukin  (IL)-5,  IL-13  and  IL-10  responses  to  mycobacteria-speciﬁc  antigens  (crude
culture  ﬁltrate  proteins  and  antigen  85)  and  non-mycobacterial  stimuli  (tetanus  toxoid  and  phyto-
haemagglutinin)  were  measured  using  ELISA.  Cytokine  responses,  scar frequency,  BCG  associated  adverse
event frequency  and  mortality  rates  were  compared  across  groups,  with  adjustments  for  potential  con-
founders.
Results:  Both  speciﬁc  and  non-speciﬁc  IFN-,  IL-13  and  IL-10  responses  in 1341  infants  differed  between
BCG  strain  groups  including  in  response  to stimulation  with  tetanus  toxoid.  BCG-Denmark  immunised
infants  showed  the highest  cytokine  responses.  The  proportion  of  infants  who  scarred  differed  signif-
icantly,  with  BCG  scars  occurring  in 52.2%,  64.1%  and  92.6%  of  infants  immunised  with  BCG  Russia,
BCG-Bulgaria  and  BCG-Denmark,  respectively  (p  <  0.001).  Scarred  infants  had  higher  IFN- and  IL-13
responses  to mycobacterial  antigens  only  than  infants  without  a scar.  The  BCG-Denmark  group  had  the
highest  frequency  of  adverse  events  (p  =  0.025).  Mortality  differences  were  not signiﬁcant.
Conclusions:  Both  speciﬁc  and  non-speciﬁc  immune  responses  to  the  BCG  vaccine  differ  by  strain.  Scarring
after BCG  vaccination  is  also  strain-dependent  and  is  associated  with  higher  IFN-  and  IL-13  responses
to  mycobacterial  antigens.  The  choice  of  BCG  strain  may  be an important  factor  and  should  be evaluated
when  testing  novel  vaccine  strategies  that  employ  BCG  in  prime–boost  sequences,  or as  a  vector  for  other
vaccine  antigens.
© 2012 Elsevier Ltd. All rights reserved.
1. Background
BCG (Bacille Calmette–Guérin), derived from Mycobacterium
bovis in 1926 [1],  is the most widely administered vaccine in
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the world, with 90.8% global coverage in 2009 [2].  Several phe-
notypically diverse strains are in use, arising from independent
subculture of attenuated mycobacteria in laboratories across the
world [3–5]. Reported efﬁcacy of BCG has varied considerably, rang-
ing from 0 to 80% [6–8], with tropical countries reporting lower
protection against tuberculosis [8,9]. Several factors that vary with
latitude may  alter BCG potency, including exposure to environmen-
tal mycobacteria [6] and other common infections in the tropics
[10]. Although BCG strain alone cannot account for the extent of
variation in efﬁcacy [8],  it may  account for some of the variation
observed in common clinical and immunological outcomes used in
research, such as BCG scarring and cytokine responses.
The ongoing problem of establishing an accurate immunological
proxy for protection against TB complicates BCG efﬁcacy studies.
0264-410X/$ – see front matter ©  2012 Elsevier Ltd. All rights reserved.
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Whilst the production of IFN- by CD4+ T cells is vital [20,21], it
is not sufﬁcient, and a more complex picture is emerging involv-
ing multiple cytokines and T cell subsets, including regulatory T
cells [20–24].  Several small human studies have compared immune
responses to different BCG strains, with variable results [11–19],
including two in Africa, which demonstrated some variability
in T cell proliferation and interferon-gamma (IFN-) production
depending on the strain and route of administration [11–13].
Besides TB, there is evidence that BCG may  also provide pro-
tection against other illnesses, with studies showing lower rates
of malaria, acute lower respiratory tract infection and overall mor-
tality in BCG-immunised individuals [14,25–27].  Such non-speciﬁc
effects of BCG have also been demonstrated immunologically, with
increased cytokine responses to both BCG-related antigens and
non-BCG antigens such as tetanus toxoid (TT) or phytohaemagglu-
tinin (PHA) amongst BCG-immunised children [28,29].
Our large birth cohort in Entebbe, Uganda, provided an oppor-
tunity to examine whether different BCG strains elicited different
immune responses to both mycobacterial and non-mycobacterial
stimuli, and to evaluate further the relationship between BCG
strain, scarring and cytokine responses.
2. Methods
2.1. Study design
The Entebbe Mother and Baby Study, a randomised double-
blind, placebo-controlled trial of the effect of anthelminthic
treatment on responses to childhood immunisations, has been
described elsewhere [10,30–32];  the following methods are rel-
evant to this analysis.
2.2. Recruitment and follow-up
Pregnant women from the Entebbe peninsula in Uganda were
screened and enrolled at Entebbe Hospital from April 2003 until
November 2005. Socio-demographic details were obtained by
questionnaire during antenatal care. Stool and blood samples were
taken for parasitological and HIV testing and babies of participat-
ing mothers were followed up. Second-born twins, babies who had
not received all three doses of tetanus vaccine and babies who
had received their BCG after 6 months or outside Entebbe Hospi-
tal (where strain data were unavailable) were excluded from this
analysis. The HIV status of HIV-exposed infants was  ascertained
through PCR of blood taken at age 6 weeks and rapid-test serology
performed at 18 months.
At age 12 months infants had blood taken for immunological
analysis; anthropometric parameters and the presence and diame-
ter of BCG scars were documented. If unwell at the time of the visit,
infants were treated accordingly and the study investigations were
conducted up to 2 months later. Throughout the study the clinic was
freely accessible as required, with any illnesses or vaccine-related
adverse events being recorded.
2.3. Immunisation
Vaccines were provided by Uganda National Medical Stores.
Nurses at Entebbe Hospital immunised babies at birth with 0.05 ml
of intradermal BCG over the right deltoid, containing the strain
and lot available at the time.2 The three strains used during the
study period were BCG-Russia (BCG-I strain from Moscow, Serum
Institute of India, India); BCG-Bulgaria (BCG-SL 222 Soﬁa strain,
2 See supplementary information for BCG lot numbers used.
BB-NCIPD Ltd., Bulgaria); and BCG-Denmark (BCG-SSI 1331, Statens
Seruminstitut, Denmark). Other vaccines administered were OPV
(at 0, 6, 10 and 14 weeks); DPT, Hib and Hep B (at 6, 10 and 14
weeks); and measles (at 9 months).
2.4. Immunological analysis
Cytokine responses were assessed by six-day whole blood cul-
ture and ELISA assay, as previously described [10]. Cytokine levels
in culture supernatants were measured by ELISA (Beckton Dickin-
son, UK) after stimulation by crude culture ﬁltrate protein, antigen
85 (cCFP, Ag 85; Colorado State University, USA), tetanus toxoid
(TT; Statens Seruminstitut, Denmark) and phytohaemagglutinin
(PHA; Sigma, UK). CFP and Ag85 were used to assess mycobacteria-
speciﬁc immune responses and PHA and TT to assess non-speciﬁc
effects of BCG strains.
IFN- and IL-10 were analysed as representative of type 1 and
regulatory activity respectively. Although IL-4 levels are central
to the type 2 response, IL-5 and IL-13 are more detectable in
supernatants and were therefore measured instead. Results were
adjusted according to responses in unstimulated wells. To avoid
time dependent effects of assay performance, the sequentially col-
lected samples were tested in a randomised order.
2.5. Statistical analysis
Statistical analyses were conducted using Stata/IC 11.1. Infants
were grouped according to strain of BCG received. Characteris-
tics of the three groups of infants and mothers were compared
using Pearson’s chi-squared test for categorical variables and the
t-test for continuous variables. Cytokine levels below the thresh-
old of detection were set to zero3; distributions of cytokine results
were highly skewed, a recognised phenomenon in immunological
studies [10,30,33].  Cytokine results were therefore transformed to
log10(concentration + 1) before analysis. Mean cytokine responses
were compared between strain groups using random effects linear
regression, anti-logging the regression coefﬁcients to obtain geo-
metric mean ratios (GMRs). Random effects were used to account
for potential between-lot variability (since several lots of vaccine
were administered within each BCG strain group). As some cytokine
results remained skewed after log10 transformation, analyses were
boostrapped [33] with 10,000 repeats to calculate bias-corrected
accelerated conﬁdence intervals. Cytokine responses of infants
with and without a BCG scar were compared using the same meth-
ods but without random effects (being independent of potential
between-lot variability).
Odds ratios for associations between BCG strain and scar pres-
ence were calculated through random effects logistic regression.
BCG scar sizes were compared across strain groups through linear
regression. Because differences in male and female infant responses
to BCG have been reported [10,14,26,34,35] all analyses were
repeated stratifying by sex, using Wald tests to assess interactions
between the effects of sex and strain.
Consistency of results was  checked between different batches of
assay antigen. The second batches of cCFP and TT appeared to pro-
duce slightly different cytokine responses. The second batch of cCFP
was only used in a small number of samples, which were therefore
excluded from analysis. However, the groups tested with different
batches of TT were of similar size and therefore cytokine responses
to TT were adjusted for TT batch to avoid loss of power.
3 The cut-off points for a positive cytokine response were set to IFN- = 73 pg/ml;
IL-5  = 34 pg/ml; IL-13 = 8 pg/ml; IL-10 = 48 pg/ml (the mean level plus two standard
deviations of the negative control).
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Table  1
Maternal and infant characteristics according to BCG-strain groups.
BCG-Russia (n = 1124) BCG-Bulgaria (n = 788) BCG-Denmark (n = 169) p-Valueb
Frequency (%)a Frequency (%)a Frequency (%)a
Maternal characteristics
Age (years)
<20 279 (25%) 183 (23%) 44 (26%)
0.765
20–24  431 (38%) 298 (38%) 55 (33%)
25–29  248 (22%) 184 (23%) 41 (24%)
30–34  108 (10%) 89 (11%) 20 (12%)
≥35 58  (5%) 34 (4%) 9 (5%)
Education (4 missing values)
None 35 (3%) 35 (4%) 5 (3%)
0.748
Primary 579 (52%) 398 (51%) 83 (49%)
Secondary 418 (37%) 287 (37%) 68 (40%)
Tertiary 92 (8%) 65 (8%) 12 (7%)
Tribe  (1 missing value)
Muganda 564 (50%) 388 (49%) 84 (50%)
0.596
Munyankole 98 (9%) 77 (10%) 15 (9%)
Mutoro 43 (4%) 36 (5%) 7 (4%)
Musoga 48 (4%) 27 (3%) 9 (5%)
Luo  71 (6%) 38 (5%) 7 (4%)
Munyawanda 60 (5%) 53 (7%) 5 (3%)
Others 240 (21%) 168 (21%) 42 (25%)
Study  area (28 missing values)
Entebbe 470 (42%) 324 (42%) 62 (37%)
0.093
Kigungu 131 (12%) 83 (11%) 19 (11%)
Manyago, Kibale 330 (30%) 205 (27%) 46 (27%)
Katabi,  roadside 97 (9%) 92 (12%) 23 (14%)
Katabi,  rural 85 (8%) 68 (9%) 18 (11%)
Household socioeconomic status (40 missing values)
1  (low) 71 (6%) 34 (4%) 10 (6%)
0.323
2 104 (9%) 67 (9%) 13 (8%)
3  347 (31%) 248 (32%) 45 (27%)
4 296  (27%) 241 (31%) 48 (29%)
5  227 (21%) 140 (18%) 41 (25%)
6  (high) 59 (5%) 41 (5%) 9 (5%)
Gravidity
1  303 (27%) 209 (27%) 46 (27%)
0.9332–4  639 (57%) 440 (56%) 93 (55%)
≥5  182 (16%) 139 (18%) 30 (18%)
Malaria parasitaemia (37 missing values)
Positive 102 (9%) 89 (11%) 22 (13%) 0.197
HIV  status
Positive 130 (12%) 94 (12%) 17 (10%) 0.788
Helminth infections (6 missing values)
Hookworm 534 (48%) 302 (38%) 70 (41%) <0.001
Schistosoma mansoni 229 (20%) 136 (17%) 26 (15%) 0.105
Mansonella perstans 232 (21%) 160 (20%) 50 (30%) 0.023
Infant  characteristics
Sex
Male 566 (50%) 412 (52%) 90 (53%) 0.617
Age  at BCG immunisation (days)
<1  257 (23%) 197 (25%) 38 (22%)
0.274
1–2  647 (58%) 417 (53%) 99 (59%)
3–7  79 (7%) 75 (10%) 11 (7%)
8–28  81 (7%) 57 (7%) 16 (9%)
29–6  months 60 (5%) 42 (5%) 5 (3%)
Malaria parasitaemia at 1 year (655 missing values)c
Positive 53 (7%) 18 (3%) 9 (7%) 0.033
HIV  status at 1 year (43 missing values)c,d
Positive 24 (2%) 21 (3%) 6 (4%) 0.478
Mean (±SD) Mean (±SD) Mean (±SD)
Birth weight (326 missing values) (kg) 3.186 (±0.476) 3.171 (±0.495) 3.179 (±0.462) 0.827
Lymphocyte count at 1 year (544 missing values)c (cells per 109/l) 6.927 (±2.683) 6.870 (±2.607) 6.625 (±2.414) 0.474
p-Values <0.05 are indicated in bold.
a indicates crude frequencies and proportions (%) of each variable outcome within each BCG strain group, unless otherwise indicated.
b p-Value for test of null hypothesis that there is no association between characteristic and BCG strain group.
c Data are only available for infants who attended the study clinic at 1 year.
d Babies were assumed to be HIV-negative if their mothers were HIV-negative, and to be HIV positive at one year if serological results were positive at age 18 months.
As different strains were administered during set periods of
time in sequence according to their availability, there was  poten-
tial for confounding by factors associated with both calendar
time and cytokine responses (Table 1) [10]. Factors considered as
a priori confounders were infant malaria parasitaemia, maternal
Mansonella perstans and hookworm infection, and area of resi-
dence (as the recruitment area was gradually expanded to include
more rural areas surrounding Entebbe and different environmental
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exposures may  inﬂuence cytokine responses). All analyses were
adjusted for the above factors as well as HIV infection, which
causes severe restriction of infant cytokine responses [10,36]. As
anthelminthic treatment allocation was randomised and was found
to have no effect on infant immune responses [30], maternal
anthelminthic was not considered as a possible confounder, or
adjusted for, in this analysis.
Mortality rates per 1000 person years were compared between
strain groups using Cox regression hazard ratios. The numbers of
BCG-related adverse events were tabulated by group and compared
using Fisher’s exact test.
2.6. Ethics statement
All mothers gave informed, written consent. Ethical approval
for the trial was granted from the Science and Ethics Committee of
the Uganda Virus Research Institute, Uganda National Council for
Science and Technology, and London School of Hygiene and Tropical
Medicine.
3. Results
3.1. Participants
Of 2345 livebirths, 2081 singleton babies received BCG at
Entebbe Hospital within 6 months of birth. Of these, 145 infants
did not have data on immunisations other than those administered
at birth; 220 infants did not receive all three doses of tetanus tox-
oid; 60 infants died or were lost to follow-up before 1 year of age;
315 infants were still in follow-up but did not provide a blood sam-
ple within the speciﬁed time frame. Therefore 1341 samples with
immunological results were eligible for this analysis. Mothers of
infants not included were in earlier stages of gestation at recruit-
ment, younger, and more likely to be ﬁrst-time mothers, of lower
socio-economic status and living in a more distant study area [30].
However, lack of eligibility was not associated with strain group.
The three groups had similar socio-demographic characteristics
(Table 1); there were however differences in maternal hookworm
and M.  perstans infection prevalence. Amongst infants, there were
no signiﬁcant differences in sex ratio, birth weights, HIV status
or mean lymphocyte counts; but malaria parasitaemia differed
between groups.
3.2. Cytokine responses and scar frequency
Cytokine responses to both mycobacteria-speciﬁc (cCFP and
Ag85) and non-speciﬁc stimuli (TT and PHA) differed between BCG
strains (Table 2). In particular, the BCG-Denmark group demon-
strated IFN- responses that were signiﬁcantly higher than those
of the BCG-Russia group to all four stimuli, as well as higher
IL-13 responses to cCFP and PHA. Compared to BCG-Russia, IL-5
responses did not differ in the BCG-Denmark group. However in
the BCG-Bulgaria group, they were marginally lower in response
to speciﬁc antigens. IL-10 levels were notably higher for both
BCG-Bulgaria and BCG-Denmark groups relative to BCG-Russia in
response to all stimuli.
Overall, 59.0% of the one-year olds had a BCG scar. There were
signiﬁcant differences between the proportions of each group who
had a BCG scar: BCG-Denmark had a markedly higher association
with scarring than BCG-Russia or BCG-Bulgaria (p < 0.001; Table 2).
BCG scar size did not signiﬁcantly differ between groups (data not
shown).
The above observations were similar after stratifying by infant
sex. For cCFP, Ag85 and PHA there was a tendency for some effects
of BCG strain to appear stronger in female infants (data not shown).
In response to TT, there was an interaction between sex and strain
for IL-10 responses (Table 3), with stronger associations amongst
female infants. However, similar proportions of girls and boys
developed a scar.
Samples from infants with BCG scars demonstrated higher IFN-
 and IL-13 responses to mycobacterial antigens, but not to TT or
PHA, than those without a scar (Table 4). There were no differences
in IL-5 or IL-10 responses by scar status for any stimulus.
3.3. BCG-related adverse events and mortality from all causes
BCG-related adverse events included 2 ulcers and 12 abscesses,
occurring in 0.3% of the BCG-Russia group, 1.0% of the BCG-Bulgaria
group and 1.8% of the BCG-Denmark group (p = 0.025). Observed
mortality appeared slightly higher in the BCG-Denmark group,
however the study was underpowered to detect signiﬁcant differ-
ences (Table 5).
4. Discussion
This infant cohort in a low-resource tropical country, recruited
before birth and followed up prospectively, provided a good oppor-
tunity to investigate potential differences between the effects of
three BCG strains that are commonly used globally. We  found
signiﬁcant differences in mycobacteria-speciﬁc and non-speciﬁc
immune responses, and in the frequency of BCG-associated adverse
events, according to the vaccine strain used. To our knowledge, this
is the largest study to evaluate the effects of BCG strain on immune
responses to the BCG vaccine and the only study to assess both
speciﬁc and non-speciﬁc responses [11].
Other studies have shown that BCG elicits type 1 and type 2
responses, to both mycobacteria-speciﬁc and non-speciﬁc stimuli
[28,29]. Non-speciﬁc effects have also been reported at the clinical
level, with reductions in non-TB infections and in overall mortality
in BCG immunised infants [14,25–27,35,36]. Furthermore, BCG has
been shown to act non-speciﬁcally as a primer for other vaccines
[29]. Here we  were able to conduct a broad analysis of the effect of
BCG strain by comparing type 1 (IFN-), type 2 (IL-5 and IL-13) and
regulatory (IL-10) responses to both mycobacteria-speciﬁc (cCFP
and Ag85) and non-speciﬁc (TT and PHA) stimuli.
The results revealed three signiﬁcant patterns of strain-
dependent variability of immune responses to both mycobacteria-
speciﬁc and non-speciﬁc stimuli: higher IFN- and IL-13 responses
in the BCG-Denmark group; lower IL-5 responses in the
BCG-Bulgaria group; and higher IL-10 responses in both the
BCG-Denmark and BCG-Bulgaria group compared to BCG-Russia.
Consistent with being at the greatest genetic distance from the
other two  strains [9],  the cytokine responses of the BCG-Denmark
group were the most divergent. Surprisingly however, they were
also the highest overall, despite being most distantly related to the
original M. bovis strain [37]. It is also interesting that BCG-Bulgaria
and BCG-Russia behaved slightly differently in this cohort, despite
being genetically identical, except for possible single nucleotide
changes [38]. As all infants were immunised with BCG, it is uncer-
tain how these ﬁndings would relate to non-speciﬁc responses
(such as the response to TT) amongst BCG-unvaccinated infants,
however, differences between strains in non-speciﬁc effects were
clearly demonstrated.
It is possible that the greater immunogenicity of BCG-Denmark
may  lead to better protection against TB. However, IFN- alone
is an insufﬁcient protective marker and it is feasible that higher
regulatory IL-10 production in the same group may counteract
its effects [39]. The observation that IL-10 production differed
between strains is contrary to a recent study [28] that found that
BCG did not stimulate an IL-10 response. This analysis suggests
that the ability of BCG to stimulate an IL-10 response may  be
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Table  2
Effect of BCG strain on cytokine responses and scar frequency.
Cytokine Assay stimulus Russia (n = 719) Bulgaria (n = 508) Denmark (n = 114)
Geometric
mean (pcg/ml)
Geometric
mean (pcg/ml)
GMRa (95% CI) Geometric
mean (pcg/ml)
GMRa (95% CI)
IFN-
cCFPb 261.9 262.8 0.96 (0.61, 2.04) 622.3 2.24 (1.42, 4.00)
Ag85  130.9 113.3 0.80 (0.46, 1.32) 278.3 2.01 (1.38, 2.69)
TTc 28.5 31.9 0.96 (0.46, 2.04) 82.6 2.41 (1.14, 4.85)
PHA 281.2 299.3 1.00 (0.62, 1.66) 891.4 3.09 (2.11, 5.71)
IL-5
cCFPb 4.4 3.3 0.70 (0.23, 0.98) 5.2 1.13 (0.81, 1.66)
Ag85  2.5 2.2 0.83 (0.71, 0.99) 3.0 1.15 (0.48, 1.82)
TTc 11.1 9.1 0.61 (0.23, 1.34) 16.3 0.92 (0.34, 2.19)
PHA 43.3 28.5 0.61 (0.35, 1.04) 93.1 2.01 (0.98, 3.81)
IL-13
cCFPb 19.4 14.4 0.74 (0.35, 1.32) 30.7 1.51 (1.14, 2.43)
Ag85 7.7  6.5 0.81 (0.52, 1.08) 10.4 1.27 (0.54, 2.02)
TTc 43.1 32.0 0.69 (0.31, 1.51) 51.3 0.95 (0.38, 2.02)
PHA  140.4 137.5 0.96 (0.60, 1.81) 342.5 2.28 (1.55, 4.14)
IL-10
cCFPb 56.3 119.7 2.17 (1.48, 4.03) 234.3 4.16 (2.85, 6.89)
Ag85  49.1 103.4 2.06 (1.27, 2.82) 78.3 1.52 (1.10, 2.21)
TTc 3.3 8.6 2.17 (1.33, 8.67) 10.3 2.59 (1.39, 6.08)
PHA  125.7 203.8 1.53 (0.99, 2.38) 360.3 2.79 (2.10, 4.24)
Russia  (n = 719) Bulgaria (n = 508) Denmark (n = 114)
BCG scar frequency (%) BCG scar frequency (%) Scar presence OR (95% CI) BCG scar frequency (%) Scar presence OR (95% CI)
352 (49.0%) 333 (65.6%) 1.84 (1.25, 2.71) 106 (92.3%) 14.28 (5.85, 34.85)
The table shows strain-speciﬁc mean cytokine responses (IFN-, IL-5, IL-13 and IL-10) to four assay stimuli: culture ﬁltrate protein (cCFP); antigen 85 (Ag85); tetanus toxoid
(TT);  and phytohaemagglutinin (PHA). Scar frequencies and proportions (%) for each BCG-strain group are also included as well as odds ratios (ORs) for scar presence. Missing
values for cCFPb, Ag85, TT and PHA assays are 252, 1, 7 and 15 respectively.
a Geometric mean ratios (GMRs) comparing responses in infants vaccinated with BCG-Bulgaria or BCG-Denmark versus BCG-Russia, with bias-corrected accelerated
conﬁdence intervals. These are adjusted for: study area, infant malaria parasitaemia, infant HIV status, maternal M.  perstans infection and maternal hookworm infection (at
1  year). A random effects model was applied to the regression calculations to allow for clustering within BCG lot groups. GMRs and ORs signiﬁcantly different from 1.00 are
indicated in bold.
b Excluding the 2nd batch of cfp antigen (see text).
c Adjusted for tetanus toxoid batch (see text).
strain-dependent, although a study that compared BCG-Denmark
to BCG-Brazil and BCG-Japan, found no such differences [16].
Importantly, the differences across groups were observed in
response to TT and PHA as well as to mycobacterial antigens,
suggesting that the non-speciﬁc effects of BCG immunisation
are likely to be dependent on the strain administered. The
ﬁnding for TT speciﬁcally indicates that BCG strain differences
can modulate the infant response to subsequent, unrelated
exposures to antigens, including vaccines (and presumably,
pathogens).
Table 3
Sex-stratiﬁed effect of BCG strain on cytokine responses to tetanus toxoid (TT) and BCG scar frequency.
Cytokine Sex (M/F) Russia (n = 719) Bulgaria (n = 508) Denmark (n = 114) Interaction
p-valueb
Geometric
mean (pcg/ml)
Geometric
mean (pcg/ml)
GMRa (95% CI) Geometric
mean (pcg/ml)
GMRa (95% CI)
IFN-
M 34.2 1.04 0.97 (0.53, 1.77) 59.2 1.31 (0.47, 3.63)
0.083F  23.9 25.23 0.88 (0.47, 1.66) 115.3 4.14 (1.47, 11.61)
IL-5
M  12.3 11.63 0.64 (0.37, 1.13) 13.6 0.60 (0.23, 1.54)
0.201F  10.0 6.94 0.57 (0.32, 1.01) 19.7 1.35 (0.52, 3.48)
IL-13
M  46.1 38.29 0.69 (0.42, 1.16) 35.1 0.50 (0.21, 1.19)
0.056F  40.4 26.28 0.67 (0.39, 1.13) 74.9 1.74 (0.73, 4.13)
IL-10
M  4.1 9.59 1.74 (1.09, 2.78) 6.7 1.08 (0.49, 2.37)
0.01F  2.7 7.70 2.73 (1.71, 4.36) 15.9 6.73 (3.13, 14.45)
Sex  (M/F) Russia (n = 719) Bulgaria (n = 508) Denmark (n = 114) p-Valuec
BCG scar frequency (%) BCG scar frequency (%) Scar presence OR (95% CI) BCG scar frequency (%) Scar presence OR (95% CI)
M 182 (51.9%) 173 (65.3%) 1.64 (1.04, 2.60) 53 (93.0%) 12.40 (3.85, 39.96)
0.557F  170 (46.3%) 160 (65.8%) 2.18 (1.36, 3.49) 53 (93.0%) 16.43 (5.12, 52.74)
The table shows strain-speciﬁc cytokine responses (IFN-, IL-5, IL-13 and IL-10) to tetanus toxoid (TT) antigen and BCG scar frequency in each BCG strain group, stratiﬁed by
sex.  There are 6 missing values (3 males and 3 females). Sex did not signiﬁcantly interact with cytokine responses to cCFP, Ag85 or PHA (data not shown).
a Geometric mean ratios (GMRs) comparing responses in infants vaccinated with BCG-Bulgaria or BCG-Denmark versus BCG-Russia, with bias-corrected accelerated
conﬁdence intervals. These are adjusted for: study area, malaria parasitaemia, HIV status, M. perstans infection and hookworm infection (at 1 year). A random effects model
was  applied to the regression calculations to allow for clustering within BCG lot groups. GMRs and ORs signiﬁcantly different from 1.00 and p-values that are <0.05 are
indicated in bold.
b p-Value for test of null hypothesis that there is no interaction of sex with the effect of strain on cytokine responses to tetanus toxoid.
c p-Value for test of null hypothesis that there is no interaction of sex with the effect of strain on BCG scar frequency.
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Table 4
Relationship between cytokine responses and BCG scar presence.
Cytokine Assay stimulus Absent scar (n = 549) Present scar (n = 791)
Geometric mean (pcg/ml) Geometric mean (pcg/ml) GMRa (95% CI)
IFN-
cCFPb 214.4 339.9 1.59 (1.21, 2.10)
Ag85  92.0 170.1 1.85 (1.43, 2.42)
TTc 27.9 36.3 1.24 (0.92, 1.68)
PHA 302.1 328.1 1.09 (0.87, 1.36)
IL-5
cCFPb 3.8 4.4 1.17 (0.91, 1.50)
Ag85  2.2 2.5 1.15 (0.95, 1.39)
TTc 37.2 41.0 1.10 (0.83, 1.47)
PHA  9.8 11.2 1.11 (0.84, 1.48)
IL-13
cCFPb 14.0 22.8 1.63 (1.26, 2.10)
Ag85 5.9 8.7 1.46 (1.17, 1.82)
TTc 39.2 38.9 0.97 (0.76, 1.26)
PHA 141.6 156.2 1.10 (0.91, 1.36)
IL-10
cCFPb 75.3 77.2 1.02 (0.82, 1.29)
Ag85  64.2 70.4 1.10 (0.89, 1.35)
TTc 5.0 5.5 1.00 (0.79, 1.26)
PHA  160.5 168.0 1.05 (0.87, 1.26)
The table compares the cytokine responses of infants, with and without BCG scars, to four assay stimuli: crude culture ﬁltrate protein (cCFP); antigen 85 (Ag85); tetanus
toxoid (TT); and phytohaemagglutinin (PHA). Missing values for cCFPb, Ag85, TT and PHA assays are 253, 2, 8 and 16 respectively.
a Geometric mean ratios (GMRs) comparing those with scars to those without are shown with bias-corrected accelerated conﬁdence intervals. GMRs signiﬁcantly different
from  1.00 are indicated in bold.
b Excluding the 2nd batch of cCFP antigen (see text).
c Adjusted for TT batch (see text).
There was striking disparity in BCG scar frequency between
groups, with an almost two-fold increase in scarring frequency
in the BCG-Denmark group compared to the BCG-Russia group.
The overall proportion with scars was 59%, despite 100% immu-
nisation coverage at birth. This is much lower than observed scar
prevalence in other populations [25,27,28,40] and is unlikely to
be attributable to poor immunisation technique considering that
93% of the BCG-Denmark group developed a scar (p < 0.001). This
analysis may  be evidence that the association between BCG scar
frequency and immunisation status is strain-dependent. BCG scars
have often been used in research to identify BCG immunised indi-
viduals, which may  be a valid method in a population uniformly
immunised with one strain, such as BCG-Denmark, which causes
the majority of vaccinees to scar. However, in populations immu-
nised with a strain that causes fewer scars, scarring may  reﬂect an
individual’s immune response to the vaccine rather than immu-
nisation status, leading to many misclassiﬁcations. In countries
using multiple strains, identifying individuals by scar status may
give results reﬂecting the effects of one strain and not the whole
immunised population. Although correlations between scar size
and cytokine responses have been demonstrated at 4 years of age
[28], it is unsurprising that no relationship was shown here, as BCG
scars are still very small at one year.
Studies in Guinea Bissau have demonstrated an association
between scar development after BCG immunisation and beneﬁt-
ing from its non-speciﬁc effects [14,25–27].  However, our results
show no correlation between scarring and non-speciﬁc cytokine
responses, with only higher mycobacteria-speciﬁc IFN- and IL-13
responses differentiating those with a scar from those without. BCG
strain did inﬂuence both non-speciﬁc immune responses and scar
development, suggesting that BCG strain could be a confounder
in the relationship between scarring and non-speciﬁc responses.
For example, the BCG-Denmark strain caused both higher
IFN- responses to non-speciﬁc stimuli and also a greater frequency
of scarring. The infants’ sex modiﬁed the effect of BCG strain on
responses to tetanus toxoid, but not to either mycobacteria-speciﬁc
antigen. This ﬁnding is in keeping with reports that girls may
experience more non-speciﬁc BCG effects than boys [14,26,35,36]
although a mechanism for this phenomenon has not been estab-
lished [36].
This study was underpowered to detect differences in mortal-
ity. However, signiﬁcant differences were detected between the
proportions of each group that experienced an adverse event, the
highest of which occurred in the BCG-Denmark group. As BCG-
Denmark stimulated the highest cytokine responses, it is possible
that there may  be a trade-off between immunogenicity and adverse
event induction, although the small number of events warrants
caution in interpreting this relationship.
Our results emphasise the importance of identifying and adjust-
ing for the strain of BCG used in studies of vaccine efﬁcacy, or of
correlates of protection, whenever BCG is employed as part of a vac-
cination strategy. This includes studies evaluating novel vaccines
that employ a prime–boost strategy, as the choice of priming BCG
strain may  inﬂuence the results. Our data also suggests that BCG
strain may  inﬂuence outcomes when employing BCG as a vector for
vaccines against other pathogens. Importantly, the choice of BCG
strain may  have clinical effects beyond the protection against TB.
Further large-scale comparative investigation of BCG strains with
clinical primary outcomes would be valuable.
This analysis was  not part of our original trial design, so infants
were not randomised to receive different BCG strains. This may
have led to potential confounders, for example, due to different
seasonal exposures to infections, which we could not account for.
However, we did identify differences in maternal helminth and
infant malaria status between the groups and we adjusted for these
variables in the analysis; adjusted results were similar to crude
Table 5
Effect of BCG strain on mortality.
BCG strain group Number of deaths from all causes Rate per 1000 person years (95% CI) Hazard ratio (95% CI) p-Value
Russia (n = 1124) 22 20.5 (13.5, 31.1) 1
0.87Bulgaria (n = 788) 14 18.6 (11.0, 31.4) 0.91 (0.46, 1.77)
Denmark (n = 169) 4 25.0 (9.4, 66.7) 1.22 (0.42, 3.53)
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ﬁndings. One-year olds were appropriate subjects as it has been
shown that IFN-, IL-5, IL-13 and IL-10 responses to BCG given at
birth are detectable at one year with some effects waning by two
years [28]. However, it was not possible to analyse TB outcomes
or long-term effects. Further work will include a repeated analy-
sis of the same cohort at ﬁve years, assessing TB prevalence and
incidence as well as non-TB illnesses and overall mortality. This
may  provide the warranted longitudinal evidence of whether or
not strain-dependent effects observed at the molecular level trans-
late to clinical outcomes in this cohort. In the meantime, whenever
multiple BCG strains are used in future research, or when the effects
of BCG or other immunisation regimes are compared in different
populations, accounting for BCG strain is vital.
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